Clinical Trial

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 29, 2021 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2015-08-26; most recent amendment 2021-11-26.
Status change: Not Yet Recruiting → Recruiting 2017-02-24
Trial Details
NCT Number NCT02535221
Lead Sponsor Peking University
Conditions Breast Cancer
Enrollment 234 participants
Start Date 2015-07-29
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-11-29